Vascular and Metabolic Effects of Vytorin

Phase 4CompletedNCT01660945

Gachon University Gil Medical Center204 enrolled

Overview

The investigator hypothesize that vytorin may improve vascular and insulin resistance in hypercholesterolemic patients

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

204

Conditions

Hypercholesterolemia

Interventions

placeboDRUG

vytorinDRUG

Eligibility

Sex: ALLMin age: 25 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * hypercholesterolemia Exclusion Criteria: * overt liver disease, chronic renal failure, hypothyroidism, myopathy, uncontrolled diabetes (HbA1c \> 9%), severe hypertension, stroke, acute coronary events, coronary revascularization within the preceding 3 months, or alcohol abuse

Locations (1)

Gil Medical Center

Incheon, South Korea

Outcomes

Primary Outcomes

flow-mediated dilation

Time frame: 8 weeks of treatment

Secondary Outcomes

insulin resistance

Time frame: 8 weeks of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.